LQDA
Liquidia Corp
NASDAQ · Healthcare · Biotechnology · US
$66.88
−2.21%Sep 10, 2026, 18:40 UTC
The FDA granted Fast Track designation to Liquidia's Yutrepia for the treatment of Raynaud's phenomenon associated with systemic sclerosis.
Source:Aug 20, 2026, 22:47 UTC
On August 20, 2026, Liquidia Corp's shares fell 5.8% to $71.05, continuing a decline from its 52-week high of $93.61.
Source:Aug 13, 2026, 05:02 UTC
Liquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially.
Source:Aug 12, 2026, 10:30 UTC
Liquidia Corporation reported second quarter 2026 financial results, with YUTREPIA net product sales of approximately $170.4 million, net income of $74.7 million, and adjusted EBITDA of $96.3 million.